Francisco Vega

Prof. Francisco Vega

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
RARita Alaggio
Rita Alaggio
CACatalina Amador
Catalina Amador
IAIoannis Anagnostopoulos
Ioannis Anagnostopoulos
AAAyoma D. Attygalle
Ayoma D. Attygalle
IAIguaracyra Barreto de Oliveira Araujo
Iguaracyra Barreto de Oliveira Araujo
WXWenbin Xiao
Wenbin Xiao
We herein present an overview of the upcoming 5thedition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4thedition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5thedition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.

1 June 2005 in Laboratory Investigation
Verified
Journal Article
Closed access
FVFrancisco Vega
Francisco Vega
CCChung-Che Chang
Chung-Che Chang
LMLeonard J Medeiros
Leonard J Medeiros
MUMark M Udden
Mark M Udden
JCJeong Hee Cho-Vega
Jeong Hee Cho-Vega
JJJeffrey L Jorgensen
Jeffrey L Jorgensen

1 January 2008 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
JCJeong Hee Cho-Vega
Jeong Hee Cho-Vega
LML. Jeffrey Medeiros
L. Jeffrey Medeiros
VPVictor G. Prieto
Victor G. Prieto
FVFrancisco Vega
Francisco Vega
Leukemia cutis (LC) is a nonspecific term used for cutaneous manifestations of any type of leukemia. LC has a wide range of cutaneous manifestations,

27 May 2021 in Blood
Verified
Journal Article
Open access
PDF file
VPVicki Plaks
Vicki Plaks
JRJohn M. Rossi
John M. Rossi
JCJustin Chou
Justin Chou
LWLinghua Wang
Linghua Wang
SPSoumya Poddar
Soumya Poddar
SNSattva S. Neelapu
Sattva S. Neelapu

1 January 2013 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
SLShaoying Li
Shaoying Li
XFXiaoli Feng
Xiaoli Feng
TLTing Li
Ting Li
SZShuang Zhang
Shuang Zhang
ZZZhuang Zuo
Zhuang Zuo
C. Cameron YinC. Cameron Yin
C. Cameron Yin
Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is uncommon in the United States. We report 73 patients with ENKTL, including 49 men and 24 women (median age, 46 y). Sixty-three patients had nasal/upper aerodigestive tract disease; 10 had extranasal disease involving skin, small intestine, epiglottis, testis, adrenal glands, kidney, and breast. Complete staging data were available for 68 patients: 44 stage I/II and 24 stage IV. Fifteen of 69 (22%) had lymphadenopathy and 10/63 had bone marrow involvement. Histologically, 67/73 (92%) showed necrosis, and 48/70 (69%) had an angiocentric/angiodestructive growth pattern. The neoplastic cells showed a wide spectrum: medium sized (n=34), mixed small and large (n=21), large (n=13), and small (n=5). In situ hybridization for Epstein-Barr virus–encoded small RNA was positive in every case. Immunohistochemical studies showed expression of cytotoxic markers (100%), T-bet (96%), CD2 (96%), CD3 (93%), CD56 (90%), and ETS-1 (64%). Ki-67 was ≥60% in 46% cases. Therapy was known for 64 patients; 14 received only chemotherapy, 8 radiation alone, and 42 received combined radiation and chemotherapy. Median survival was 4.2 years, and 5-year overall survival was 46% (median follow-up, 3.8 y). Extranasal disease, high International Prognostic Index score, and high proliferation rate correlated with poorer prognosis. We conclude that ENKTL cases in the United States are similar to those reported in Asia and other countries. Absence of the angiocentric/angiodestructive pattern and presence of lymphadenopathy, features underemphasized in the literature, occurred in appreciable subsets of patients. The International Prognostic Index score, anatomic site of disease, and proliferation rate had prognostic value in this patient cohort.

1 July 2006 in Cancer Research
Verified
Journal Article
Closed access
PDF file
FVFrancisco Vega
Francisco Vega
LML. Jeffrey Medeiros
L. Jeffrey Medeiros
VLVasiliki Leventaki
Vasiliki Leventaki
CACoralyn Atwell
Coralyn Atwell
JCJeong Hee Cho-Vega
Jeong Hee Cho-Vega
GRGeorge Z. Rassidakis
George Z. Rassidakis
Anaplastic lymphoma kinase (ALK)–positive anaplastic large cell lymphoma (ALCL) frequently carries the t(2;5)(p23;q35) resulting in aberrant expression of chimeric nucleophosmin-ALK. Previously, nucleophosmin-ALK has been shown to activate phosphatidylinositol 3-kinase (PI3K) and its downstream effector, the serine/threonine kinase AKT. In this study, we hypothesized that the mammalian target of rapamycin (mTOR) pathway, which functions downstream of AKT, mediates the oncogenic effects of activated PI3K/AKT in ALK+ ALCL. Here, we provide evidence that mTOR signaling phosphoproteins, including mTOR, eukaryotic initiation factor 4E–binding protein-1, p70S6K, and ribosomal protein S6, are highly phosphorylated in ALK+ ALCL cell lines and tumors. We also show that AKT activation contributes to mTOR phosphorylation, at least in part, as forced expression of constitutively active AKT by myristoylated AKT adenovirus results in increased phosphorylation of mTOR and its downstream effectors. Conversely, inhibition of AKT expression or activity results in decreased mTOR phosphorylation. In addition, pharmacologic inhibition of PI3K/AKT down-regulates the activation of the mTOR signaling pathway. We also show that inhibition of mTOR with rapamycin, as well as silencing mTOR gene product expression using mTOR-specific small interfering RNA, decreased phosphorylation of mTOR signaling proteins and induced cell cycle arrest and apoptosis in ALK+ ALCL cells. Cell cycle arrest was associated with modulation of G1-S-phase regulators, including the cyclin-dependent kinase inhibitors p21waf1 and p27kip1. Apoptosis following inhibition of mTOR expression or function was associated with down-regulation of antiapoptotic proteins, including c-FLIP, MCL-1, and BCL-2. These findings suggest that the mTOR pathway contributes to nucleophosmin-ALK/PI3K/AKT-mediated tumorigenesis and that inhibition of mTOR represents a potential therapeutic strategy in ALK+ ALCL. (Cancer Res 2006; 66(13): 6589-97)